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Surveillance of viral pathogens in Australia
For many years, a sentinel laboratory system, the Laboratory Virology and Serology Reporting Scheme
(LabVISE) has been collecting data on viral pathogens of public health importance in Australia. This report is
one in a series of articles focussing on the epidemiology of viruses and viral groups under surveillance through
LabVISE which are of current public health interest.
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Introduction
Since the identification of respiratory syncytial virus
(RSV) in the late 1950s, it has been recognised as a
major cause of lower respiratory tract infection in
young children.1 RSV is a member of the
paramyxovirus family, an RNA virus related to other
respiratory viruses such as influenza and parainfluenza.
In the United States of America in 1991, disease
caused by RSV was estimated to be responsible for
the hospitalisation of 100,000 children at a cost of
US$300 million.2 The significance of RSV infections
is the high rates of infection in very young infants, and
the difficulties in diagnosis, treatment and vaccination
of this high-risk group. Given this, the progress
towards the development of therapies to prevent
infection, or at least prevent the potentially severe
consequences of infection, have been watched with
great interest.
RSV infections peak annually in winter or spring in
temperate climates. The annual peak of RSV infection
tends to occur in the absence of other respiratory viral
pathogens.1 Annual RSV epidemics are associated
with a relative decline in infections with the parainfluenza
viruses and other respiratory viruses. Influenza
epidemics tend to occur as the RSV epidemic declines,
although RSV and influenza epidemics may coincide.
The reasons for this ‘interference phenomenon’ in the
epidemiology of RSV and other respiratory viruses
remain unclear.
Viral shedding in respiratory secretions is as high as
107/ml in the nasal discharges of infected children.
While person-to-person transmission occurs, there
is evidence that transmission through contaminated
fomites is also important.3 Fomites are particularly
important in hospital settings where nosocomial
infection with RSV in paediatric wards is a significant
problem.4 Direct inoculation of contagious secretions
from the hands into the eyes and nose of carers,
leads to outbreaks of RSV in families and among
hospital staff.2
RSV infection occurs repetitively in children as
infection with RSV does not cause lasting protective
immunity. A longitudinal study in a day care centre5
showed that 98 per cent of children became infected
on their first exposure to RSV, a second exposure
resulted in 74 per cent of children being infected and
65 per cent of children were infected on a third
exposure. There are some well-defined groups of
children who are at increased risk of RSV infection.
These include children of lower socioeconomic
status, children who share a bedroom with more than
two other children, children who attend day-care,
have siblings in pre-school or school or are in a
multiple birth set. Children who are born prematurely
or have chronic lung disease or congenital heart
disease are at a higher risk of severe RSV disease
resulting in admission to hospital.6 RSV has also
been recognised as an important infection in solid
organ and haemopoietic stem cell transplant patients
of all ages.7
Although infants are recognised as the group with
the largest burden of RSV disease, infections with
the virus resulting in illness continue throughout life.
The importance of RSV in the elderly has been
recognised. Four per cent of adults with community-
acquired pneumonia hospitalised during the RSV
season had serological evidence of current RSV
infection.8 More recently it has been recognised that
a substantial proportion (between 7 and 41 per cent)
of ‘influenza-like illness’ reported to general practices
in the United Kingdom was due to RSV infection.9
Strains of RSV found in the community and hospital
patients in the same year were similar although
lineages of RSV varied year by year. These are
important findings for the development and use of
vaccines and anti-viral agents against respiratory
viruses.
Pathogenesis
Primary infection with RSV occurs with the highest
incidence in infants aged between two and eight
months.6 The infection is rarely asymptomatic with
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pneumonia, bronchiolitis and tracheobronchitis being
the major clinical manifestations. Otitis media may
occur in 30 to 40 per cent of infected infants. RSV is
responsible for between 50 and 90 per cent of
hospital admissions for bronchiolitis, 5 to 40 per cent
of those for pneumonia and 10 to 30 per cent of those
for tracheobronchitis in children.2 RSV viruses invade
the epithelial cells of the lower respiratory tract and
spread from cell to cell by inducing cell fusion and the
formation of syncytia. Ciliated epithelium is destroyed
and necrosis is observed.10 The sloughing-off of the
epithelia and increased secretion of mucus obstruct
small airways leads to the clinical symptoms of
bronchiolitis (inflammation of the bronchioles). These
symptoms include hyperinflation, atelectasis (absence
of gas in part of lung due to failure of alveolar
expansion) and wheezing.2 Treatment of RSV infection
in infants is largely supportive and may include
administration of supplemental oxygen, mechanical
ventilation and fluid replacement. Bronchodilator
therapy with alpha- and beta-agonists have been
used but their efficacy is uncertain.6 Treatment with
aerosolised ribavirin, a synthetic nucleoside with
antiviral properties, was licensed for use in hospitalised
children with RSV infection in the United States of
America in 1985.10 A recent review of randomised
trials of ribavirin11 suggests that anti-viral treatment
reduces the length of ventilator support and possibly
the duration of hospital stay. Larger studies are
required to fully assess the efficacy of this treatment.
Various factors have been postulated to influence
the clinical severity of RSV disease in infants. Infants
with compromised respiratory function, such as
bronchopulmonary dysplasia or congenital heart
disease with increased pulmonary circulation, are at
increased risk of severe RSV disease.12 There have
been suggestions that group A RSV viruses cause
more severe disease than group B, but the evidence
is inconclusive.12 More recent studies have suggested
the GA3 clade of group A RSV causes more severe
disease than clades GA2 or GA4.13 The viral load in
infants with severe RSV disease has been shown to be
10-fold higher than that in infants with mild disease.14
RSV viral load seems to be associated with lung
consolidation and hypoxia.15 However, other studies
have shown no relation between viral titre and
severity of illness,16 possibly because of difficulties in
determining when the peak in viral shedding occurs.
Investigations of the pathogenesis of RSV disease
have shown a relationship between a single
nucleotide polymorphism in the upstream sequence
of the interleukin 8 (IL–8) gene. This polymorphism is
associated with increased IL–8 production, which is
a potent neutrophil chemoattractant. This allele was
demonstrated to occur more frequently in infants with
RSV bronchiolitis.17 IL–8 levels in plasma are
increased in infants with severe RSV disease12 and
neutrophils are predominant in RSV bronchiolitis.18
Further clues to the pathogenesis of RSV come from
the trials of the formalin-inactivated RSV vaccine
(FI–RSV) in the 1960s, which showed increased
morbidity and mortality in vaccine recipients when
infected with RSV. Enhanced RSV disease seen in
vaccine recipients may have been mediated by the
formation of immune complexes and the subsequent
activation of complement resulting in haemorrhagic
necrosis in the lung.19
Approximately 70 per cent of wheezing episodes in
the first year of life are associated with respiratory
viral infections. RSV, rhinovirus and influenza B are
the most frequently identified viruses.20 Following
RSV infection, subsequent wheezing has been noted
in 40 to 50 per cent of infants hospitalised with RSV
bronchiolitis.2 These infants have a higher risk of
wheezing and abnormal pulmonary function for up to
10 years.6 Exacerbation of existing asthma by
respiratory viruses has been noted, with an asthma
attack in 50 to 70 per cent of cases with culture
confirmed rhinovirus, RSV or coronavirus infection.20
A cohort study showed that children with RSV lower
respiratory tract infection before age three had a
threefold increased risk of infrequent wheeze and a
fourfold increased risk of frequent wheeze up to the
age of 6 years. The risk of wheeze declined in this
group thereafter and by age 13 this group of children
were no longer at increased risk.21 These data are
suggestive of an important role for RSV in the
inception of childhood asthma via modulation of the
local immune response or changes in the neural
pathways to the lungs.22 Control of the current
‘epidemic’ of asthma in Western countries may be
achieved by reducing viral respiratory infections
through vaccination.
Prevention of RSV: prophylaxis and vaccination
Two strategies have been employed in the prevention
of RSV infection. The passive immunisation of at-risk
groups using antibodies to RSV and active
immunisation with vaccines. Antibodies are important
in protection from RSV disease, especially neutralising
antibodies directed to the RSV proteins responsible
for viral attachment (G protein) and cell fusion
(F protein).18 Parenteral administration of pooled
immunoglobulin with high titres of RSV neutralising
antibody (RSVIG) given monthly as prophylaxis
during RSV season has been shown to reduce the
frequency of infections and consequent hospitalisations.
RSVIG has been used in high-risk infants, but
requires the administration of a large volume at
monthly intervals, which is expensive and exposes
infants to the risks associated with blood products.
Cost effective use of RSVIG appears to be limited to
children with bronchopulmonary dysplasia, where
one hospitalisation is prevented by the treatment of
12 children with RSVIG.10 More recently a RSV
monoclonal antibody, (‘Palivizumab’, Med Immune,
Gaithersburg, MD) has been licensed as a prophylactic
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agent for RSV in high-risk infants. A randomised,
double-blind, placebo controlled trial of ‘ Palivizumab’
in three countries demonstrated that monthly
administration during the RSV season resulted in a
55 per cent reduction in hospital admissions for RSV
infection as well as a shortening of hospital stay and
less need for intensive care unit admission and oxygen
support.23 In the absence of a vaccine, ‘Palivizumab’
is the most effective prophylaxis against RSV in
at-risk children.
The development of vaccines against RSV is
complicated by the need to induce an effective immune
response in very young infants and in the presence
of maternal antibodies. Naturally acquired immunity
is neither complete nor durable, although protection
from severe disease occurs after primary infection.2
A RSV vaccine would ideally protect at-risk children
who may be deficient in their immune responses. The
type of protective immunity to be induced by a vaccine
is uncertain, as the balance of different effector
mechanisms of the immune system in pathogenesis
or protection in RSV disease is unclear. Natural
immunity may be limited to groups or even clades of
the RSV virus and a vaccine would need to induce
broad immunity. RSV vaccine development is haunted
by the exacerbation of RSV disease induced by the
formalin-inactivated vaccines (FI–RSV) in the 1960s.
Current strategies in RSV vaccine development
cover a broad range of new vaccine technologies
including sub-unit, live attenuated and DNA vaccines
and adenovirus and poxvirus vaccine vectors.12 Live
vaccines are more likely to be effective in infants and
live attenuated cold-passaged temperature sensitive
RSV vaccines have been tested in adults and
seropositive and seronegative children.24 Although
there was no exacerbation of RSV disease in
vaccinated children or reversion of the vaccine virus
to virulence, the protective efficacy of these vaccines
has yet to be demonstrated. The introduction of safe
and effective vaccines against RSV into childhood
vaccination schedules appears to be some years
away.
Local epidemiology
In temperate regions of Australia, RSV infections
occur in sharply defined annual winter epidemics.
RSV infection is not a notifiable disease in Australia
so local information about the disease is limited to
surveillance systems such as LabVISE, hospitalisation
and mortality data and published research literature.
LabVISE reports of RSV numbered between 2,555
and 4,640 annually between 1991 and 2000. The
annual peak in cases occurred in July each year,
with between 55 and 77 per cent of all cases
identified between July and September (Figure 1).
In 2000, 87 per cent of reports were in children aged
less than 5 years, 64 per cent in children less than
one year, 44 per cent in infants aged less than
6 months and 35 per cent in children aged less than
3 months (Figure 2). Overall, the male to female ratio
was 1.3:1.
The peak in LabVISE reports of RSV infection
coincided with the peak in hospitalisations for acute
bronchiolitis, of children aged less than one year
(National Hospital Morbidity database, Australian
Institute of Health and Welfare, Figure 3). Bronchiolitis
accounted for 56 per cent of all admissions to
Australian hospitals of infants aged less than one
year in 2000/01. The number of LabVISE reports of
RSV was of the same order as total admissions for
acute bronchiolitis (Figure 3). It is likely LabVISE
captures the majority of hospitalised cases of RSV
through its network of tertiary hospital laboratories in
major Australian cities.
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Figure 1. Laboratory reports to LabVISE of
respiratory syncytial virus infection,
Australia, 1991 to 2001, by month of
specimen collection
Figure 2. Laboratory reports to LabVISE of
respiratory syncytial virus infection,
Australia, 2000, by age and sex
The relationship between the annual peaks in
reports to LabVISE of RSV and human parainfluenza
virus type 3 (HPIV–3) and influenza A and B over
three seasons is shown in Figure 4. Peaks in RSV
activity precede those of HPIV–3 (Panel A) and in
some seasons precede, and in other seasons
coincide with, peaks in activity of influenza A and B.
Given the ubiquitous nature of RSV infection in infants
and young children, there are surprisingly few
publications about the incidence or impact of this
virus in Australia. Identification of RSV epidemics in
Melbourne in 1960 and 1961 confirmed overseas
findings of a distinct peak in cases in winter months,
a strong link with bronchiolitis and a predilection for
infecting infants and young children, causing deaths
in the very young.25,26 The severity of the RSV season
in children varied from year-to-year and produced a
clinical illness distinguishable from that caused by
other viral respiratory pathogens, such as influenza
and parainfluenza.26 The possibility of intra-household
transmission was raised with the identification of
similar illnesses in the siblings of discharged children.26
Australian papers since this time have largely
consisted of case series reporting hospitalisation
episodes with RSV identification, or bronchiolitis and
other consistent clinical syndromes.27,28,29,30 These
papers confirm RSV as the major respiratory
pathogen causing lower respiratory tract infections in
infants and young children, and the seasonal nature
of the annual RSV epidemics in Australia. A three
year prospective study demonstrated the dominance
of RSV group A infection, but suggested RSV group
A and group B were similar in relation to relative
clinical severity of infection.30 Nosocomial
transmission of RSV in a paediatric teaching hospital
in New South Wales using at-risk days for
hospital-acquired RSV as the denominator, showed
the rate of transmission was 2.9 cases per 1,000
at-risk days.31
The epidemiology of RSV in New South Wales was
further examined in a review of laboratory isolations,
hospital admissions for acute bronchiolitis, and
deaths due to acute bronchiolitis.32 From January
1993 to December 1997 there were between 770 and
1,131 isolations of RSV annually, with the majority of
these occurring in children less than six months of
age. Between 1990 and 1995 there were 22,969
admissions where the principal diagnosis was acute
bronchiolitis, with approximately three-quarters
occurring in infants less than 6 months of age. There
were 7 deaths from acute bronchiolitis in New South
Wales children between 1992 and 1996 — five in
infants aged less than 3 months, and the other
2 children aged between one and 2 years of age.32
Other papers have examined therapeutic options
in the management of patients with RSV infections.
A study on the use of RSV immunoglobulin or
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Figure 3. Laboratory reports to LabVISE of
respiratory syncytial virus infection
and hospitalisations with a principle
diagnosis of bronchiolitis* in children
aged less than one year, Australia,
1996 to 2001, by month of report or
separation
* ICD–10AM code J21
Figure 4. Laboratory reports to LabVISE of
respiratory syncytial virus infection
and human parainfluenza virus type 3
(HPIV–3), (Panel A) and influenza A
and B (Panel B), Australia, 1999 to
2001, by month of report
monoclonal antibody to prevent hospitalisation and
reduce the length of stay in hospital for Australian
children with RSV, came to the conclusion that its
routine use was inappropriate, even in children at
high risk of serious consequences of infection.33
The importance of bronchiolitis in Australian
Indigenous children has been assessed to determine
whether this group is at higher risk. Rates of hospital
admission for lower respiratory tract infections were
compared in Indigenous and non-Indigenous children
born in Western Australia during 1986, using linked
hospitalisation and birth and death datasets.34 The
cumulative incidence of hospitalisation for bronchiolitis
(not RSV specific), in the first 2 years of life was 116
admissions per 1,000 live births in Indigenous children,
compared with 15 admissions per 1,000 live births in
non-Indigenous children. While there may be other
causes of bronchiolitis in Indigenous children, a review
of hospitalisation for RSV proven bronchiolitis in
Townsville from January 1997 to October 1999,
showed that the annual admission rate was
46 admission per 1,000 live births in Indigenous
children compared with 14 admissions per 1,000 live
births in non-Indigenous children.35 There was a
seasonal variation in hospitalisations in Indigenous
children with March being the peak month for RSV
admissions, but there was apparently no seasonality
in admissions for non-Indigenous children. This peak
in RSV activity is distinct from the peak seen in
national hospitalisation data (Figure 3) because
Townsville is in a tropical region of Australia.
Surveillance of RSV
Given the ubiquity of RSV infection in childhood,
what kind of disease surveillance is appropriate in
Australia? Laboratory surveillance for RSV through
LabVISE appears to routinely capture data on a large
proportion of hospitalised cases of RSV annually, in
a timely fashion and provides important information
on the interaction between the epidemiology of RSV
and other respiratory viruses. The surveillance of
influenza-like illness through sentinel general practice
schemes such as the Australian Sentinel Practice
Research Network, indirectly measures the annual
impact of RSV epidemics on community respiratory
disease. Since RSV infection in older children and
adults may not be readily distinguished from infection
with influenza and other respiratory viruses, there is
a need for simpler diagnostic tools for RSV to assess
the true dimensions of the RSV disease burden. For
the past several seasons, Victorian influenza
surveillance has provided laboratory support to
sentinel sites. In 2001, samples from patients
presenting with influenza-like illness were tested by
multiplex polymerase chain reaction for influenza A
and B, RSV, adenovirus, enterovirus and rhinovirus.36
This project will be important in defining the relative
contribution of RSV to influenza-like illness in Australia.
Conclusions
Acute respiratory infections in children accounted for
an estimated 1.9 million deaths in 2000 worldwide;
70 per cent of these deaths occurred in Africa and
South-East Asia.37 Preventing RSV-associated
morbidity and mortality through vaccination is a high
priority. RSV is the principal cause of bronchiolitis
and a major contributor to other lower respiratory
tract infections, particularly in the very young. In the
coming years, there may be new vaccines to prevent
infection and/or the serious consequences of infection
due to viral respiratory pathogens, such as RSV,
parainfluenza viruses, and influenza viruses.
Monitoring the relative importance of these infections
and collecting more comprehensive information about
their incidence and impact in our community are
important prerequisites for the implementation of
appropriate vaccine strategies. Use of surveillance
data (from systems such as LabVISE and the
Australian Institute of Health and Welfare
hospitalisation and death data), expansion of sentinel
influenza surveillance systems to include other
respiratory viral pathogens, and targeted research
studies appear to be the most efficient means of
gathering these data in Australia.
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